ZeroHarm Sciences Raises ₹65 Crore in Series A to Scale Indian Nano-Nutraceuticals Globally
What is the news?
ZeroHarm Sciences, a pioneer in nano-formulated plant-based nutraceuticals, has successfully secured ₹65 crore ($7.15 million) in its Series A funding round. The investment was led by Kotak Alternate Asset Managers Limited through its Kotak Life Sciences Fund I, contributing ₹40 crore, alongside Alkemi Growth Capital, which invested ₹25 crore. Founded in 2020 by the entrepreneurial duo Sachin and Shweta Darbarwar, the Hyderabad-based startup is on a mission to redefine the global supplement industry through measurable health outcomes and technological integration.
Why is it interesting?
The core of ZeroHarm’s innovation lies in its proprietary nano-formulation technology, which breaks down plant nutrients into nano-sized particles. This process ensures higher bioavailability, allowing for lower dosages with superior efficacy compared to traditional supplements. The company currently manages over 60 SKUs across diverse categories, including diabetes management, oncology support, and women’s wellness, serving a growing base of over 300,000 customers.
With this fresh infusion of capital, ZeroHarm Sciences is set to accelerate its international expansion, specifically targeting markets in the USA, UK, and the Middle East. By combining ancient Ayurvedic wisdom with advanced nanotechnology and a sustainable supply chain involving 10,000+ Indian farmers, ZeroHarm is a prime example of a “Global Indian Alpha” company building local intellectual property to solve global health challenges.
Read more: ZeroHarm Sciences raises Rs 65 Cr in Series A round